NFKB1 and osteoporosis: further confirmed that TMAO promotes osteoclast differentiation through NF-κB signaling pathway activation (Zhao et al., 2024), while excessive osteoclast activation accelerates bone loss and significantly increases osteoporosis and osteoarthritis risk (Veis and O’Brien, 2023).